研究发现,在接受骨髓移植治疗者中,与捐赠者相配的化疗治疗不尽如人意,降低了GVHD在骨髓移植接受者中的风险。 Study finds less-than-perfectly matched donor chemotherapy reduces GVHD risk in bone marrow transplant recipients.

MSK研究表明,由与捐赠者不完全匹配的施用者进行的静脉细胞/骨髓移植的化疗后细胞/骨髓化疗可大大降低移植后宿主疾病(GVHD)的风险。 MSK study shows that chemotherapy post-stem cell/bone marrow transplant from less than perfectly matched donors significantly reduces graft-versus-host disease (GVHD) risk. 接受化疗的与捐助者部分匹配的病人的结果几乎与与捐助者完全匹配的病人一样好。 Outcomes for patients with partially matched donors who received chemotherapy were nearly as good as those with fully matched donors. 该研究涉及1万多名骨髓移植接受者,并展示了对细胞状态变化的新认识,即抗治疗前列腺癌的细胞状态变化,突出了各种细胞状态。 The study involved over 10,000 bone marrow transplant recipients and demonstrated new insights into cell state changes in treatment-resistant prostate cancer, highlighting a wide variety of cell states.